MFDS approved cell therapy trials in South Korea, while Liminatus faces delisting pressure from Nasdaq.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MFDS approved cell therapy trials in South Korea, while Liminatus faces delisting pressure from Nasdaq.